Female Sexual Dysfunction - Pipeline Review, H2 2017
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Female Sexual Dysfunction - Pipeline Review, H2 2017
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Pipeline Review, H2 2017, provides an overview of the Female Sexual Dysfunction (Womens Health) pipeline landscape.
Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Womens Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Female Sexual Dysfunction (Womens Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 8, 5 and 3 respectively.
Female Sexual Dysfunction (Womens Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Womens Health).
- The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Womens Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Womens Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Sexual Dysfunction (Womens Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Womens Health)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Womens Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Womens Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Pipeline Review, H2 2017, provides an overview of the Female Sexual Dysfunction (Womens Health) pipeline landscape.
Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Womens Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Female Sexual Dysfunction (Womens Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 8, 5 and 3 respectively.
Female Sexual Dysfunction (Womens Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Womens Health).
- The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Womens Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Womens Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Sexual Dysfunction (Womens Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Womens Health)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Womens Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Womens Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
TABLE OF CONTENTS
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Female Sexual Dysfunction - Overview
Female Sexual Dysfunction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Female Sexual Dysfunction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Sexual Dysfunction - Companies Involved in Therapeutics Development
Allergan Plc
Callitas Therapeutics Inc
Emotional Brain BV
EndoCeutics Inc
Fabre-Kramer Pharmaceuticals Inc
GlaxoSmithKline Plc
M et P Pharma AG
Palatin Technologies Inc
Pivot Pharmaceuticals Inc
Re-Pharm Ltd
S1 Biopharma Inc
Strategic Science & Technologies LLC
TherapeuticsMD Inc
Female Sexual Dysfunction - Drug Profiles
(buspirone hydrochloride + testosterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(sildenafil citrate + testosterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bremelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
estradiol acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FKW-00GA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gepirone hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PVT-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S1B-3006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S1B-307 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SIP-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Estrogen Receptor for Female Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize Melanocortin 4 Receptor for Diabetes, Obesity, Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WC-3011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Female Sexual Dysfunction - Dormant Projects
Female Sexual Dysfunction - Discontinued Products
Female Sexual Dysfunction - Product Development Milestones
Featured News & Press Releases
Dec 19, 2017: TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act Date for TX-004HR
Nov 29, 2017: TherapeuticsMD Announces Resubmission of New Drug Application for TX-004HR
Nov 06, 2017: TherapeuticsMD Announces Plan to Resubmit the New Drug Application for TX-004HR
Nov 03, 2017: TherapeuticsMD Provides Update on TX-004HR
Oct 11, 2017: Callitas Announces Positive FDA Response to Extrinsa Pre-IND Submission
Oct 05, 2017: TherapeuticsMD Announces Multiple Presentations Related to TX-004HR at NAMS 2017
Sep 14, 2017: TherapeuticsMD Announces Submission of Additional Endometrial Safety Information to the New Drug Application for TX-004HR
Aug 10, 2017: TherapeuticsMD Provides Regulatory Update On TX-004HR
Jul 24, 2017: AMAG Pharmaceuticals Launches Intrarosa (prasterone) in the U.S. - a Novel Product to Treat Moderate to Severe Dyspareunia Due to Menopause
Jul 18, 2017: M Pharmaceutical Plans to Submit Extrinsa PIND Meeting Request Letter and Package to US FDA
Jul 17, 2017: TherapeuticsMD Provides Update on TX-004HR
Jul 14, 2017: M Pharmaceutical Provides Update on Extrinsa
Jun 06, 2017: M Pharmaceutical Receives USPTO Trademark Protection for Extrinsa for the Treatment of Female Sexual Dysfunction
May 08, 2017: TherapeuticsMD Receives Complete Response Letter from FDA for TX-004HR New Drug Application
May 02, 2017: TherapeuticsMD to Host TX-004HR Regulatory Update Conference Call and Webcast
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Number of Products under Development for Female Sexual Dysfunction, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Female Sexual Dysfunction - Pipeline by Allergan Plc, H2 2017
Female Sexual Dysfunction - Pipeline by Callitas Therapeutics Inc, H2 2017
Female Sexual Dysfunction - Pipeline by Emotional Brain BV, H2 2017
Female Sexual Dysfunction - Pipeline by EndoCeutics Inc, H2 2017
Female Sexual Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2017
Female Sexual Dysfunction - Pipeline by GlaxoSmithKline Plc, H2 2017
Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H2 2017
Female Sexual Dysfunction - Pipeline by Palatin Technologies Inc, H2 2017
Female Sexual Dysfunction - Pipeline by Pivot Pharmaceuticals Inc, H2 2017
Female Sexual Dysfunction - Pipeline by Re-Pharm Ltd, H2 2017
Female Sexual Dysfunction - Pipeline by S1 Biopharma Inc, H2 2017
Female Sexual Dysfunction - Pipeline by Strategic Science & Technologies LLC, H2 2017
Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, H2 2017
Female Sexual Dysfunction - Dormant Projects, H2 2017
Female Sexual Dysfunction - Dormant Projects, H2 2017 (Contd..1), H2 2017
Female Sexual Dysfunction - Discontinued Products, H2 2017
Number of Products under Development for Female Sexual Dysfunction, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Female Sexual Dysfunction - Overview
Female Sexual Dysfunction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Female Sexual Dysfunction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Sexual Dysfunction - Companies Involved in Therapeutics Development
Allergan Plc
Callitas Therapeutics Inc
Emotional Brain BV
EndoCeutics Inc
Fabre-Kramer Pharmaceuticals Inc
GlaxoSmithKline Plc
M et P Pharma AG
Palatin Technologies Inc
Pivot Pharmaceuticals Inc
Re-Pharm Ltd
S1 Biopharma Inc
Strategic Science & Technologies LLC
TherapeuticsMD Inc
Female Sexual Dysfunction - Drug Profiles
(buspirone hydrochloride + testosterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(sildenafil citrate + testosterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bremelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
estradiol acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FKW-00GA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gepirone hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PVT-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S1B-3006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S1B-307 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SIP-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Estrogen Receptor for Female Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize Melanocortin 4 Receptor for Diabetes, Obesity, Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WC-3011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Female Sexual Dysfunction - Dormant Projects
Female Sexual Dysfunction - Discontinued Products
Female Sexual Dysfunction - Product Development Milestones
Featured News & Press Releases
Dec 19, 2017: TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act Date for TX-004HR
Nov 29, 2017: TherapeuticsMD Announces Resubmission of New Drug Application for TX-004HR
Nov 06, 2017: TherapeuticsMD Announces Plan to Resubmit the New Drug Application for TX-004HR
Nov 03, 2017: TherapeuticsMD Provides Update on TX-004HR
Oct 11, 2017: Callitas Announces Positive FDA Response to Extrinsa Pre-IND Submission
Oct 05, 2017: TherapeuticsMD Announces Multiple Presentations Related to TX-004HR at NAMS 2017
Sep 14, 2017: TherapeuticsMD Announces Submission of Additional Endometrial Safety Information to the New Drug Application for TX-004HR
Aug 10, 2017: TherapeuticsMD Provides Regulatory Update On TX-004HR
Jul 24, 2017: AMAG Pharmaceuticals Launches Intrarosa (prasterone) in the U.S. - a Novel Product to Treat Moderate to Severe Dyspareunia Due to Menopause
Jul 18, 2017: M Pharmaceutical Plans to Submit Extrinsa PIND Meeting Request Letter and Package to US FDA
Jul 17, 2017: TherapeuticsMD Provides Update on TX-004HR
Jul 14, 2017: M Pharmaceutical Provides Update on Extrinsa
Jun 06, 2017: M Pharmaceutical Receives USPTO Trademark Protection for Extrinsa for the Treatment of Female Sexual Dysfunction
May 08, 2017: TherapeuticsMD Receives Complete Response Letter from FDA for TX-004HR New Drug Application
May 02, 2017: TherapeuticsMD to Host TX-004HR Regulatory Update Conference Call and Webcast
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List Of Tables
Number of Products under Development for Female Sexual Dysfunction, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Female Sexual Dysfunction - Pipeline by Allergan Plc, H2 2017
Female Sexual Dysfunction - Pipeline by Callitas Therapeutics Inc, H2 2017
Female Sexual Dysfunction - Pipeline by Emotional Brain BV, H2 2017
Female Sexual Dysfunction - Pipeline by EndoCeutics Inc, H2 2017
Female Sexual Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2017
Female Sexual Dysfunction - Pipeline by GlaxoSmithKline Plc, H2 2017
Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H2 2017
Female Sexual Dysfunction - Pipeline by Palatin Technologies Inc, H2 2017
Female Sexual Dysfunction - Pipeline by Pivot Pharmaceuticals Inc, H2 2017
Female Sexual Dysfunction - Pipeline by Re-Pharm Ltd, H2 2017
Female Sexual Dysfunction - Pipeline by S1 Biopharma Inc, H2 2017
Female Sexual Dysfunction - Pipeline by Strategic Science & Technologies LLC, H2 2017
Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, H2 2017
Female Sexual Dysfunction - Dormant Projects, H2 2017
Female Sexual Dysfunction - Dormant Projects, H2 2017 (Contd..1), H2 2017
Female Sexual Dysfunction - Discontinued Products, H2 2017
List Of Figures
Number of Products under Development for Female Sexual Dysfunction, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
RELATED REPORTS
Female Contraception Global Clinical Trials Review, H1, 2020
Female Contraception Global Clinical Trials Review, H1, 2020Its clinical trial report, Female Contraception Global Clinical Trials Review, H1, 2020 provides an overview of Female Contraception Clinical trials scenario. This report
View ReportCOVID-19 Outbreak-Global Female Hypoactive Sexual Desire Disorder Therapeutics Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
Hypoactive sexual desire disorder (HSDD) is a common multifactorial condition which is characterized by a decrease in sexual desire that causes marked personal distress and/or interpersonal difficulty.The Female Hypoactive Sexual
View ReportMale Sexual Dysfunction (Male Health) - Drugs in Development, 2021
Male Sexual Dysfunction (Male Health) - Drugs in Development, 2021Male Sexual Dysfunction (Male Health) - Drugs in Development, 2021 provides an overview of the Male Sexual Dysfunction pipeline landscape.The report
View ReportFemale Sexual Dysfunction - Pipeline Review, H1 2020
Female Sexual Dysfunction - Pipeline Review, H1 2020 latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2020, provides an overview of the Female Sexual
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
